Nuo Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Apr 1, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Apr 1, 2025

AURXStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Special Note Regarding Forward-Looking Statements
Trademarks
PART I	1
ITEM 1. Business	1
ITEM 1A. Risk Factors	8
ITEM 1B. Unresolved Staff Comments	17
ITEM 1C. Cybersecurity	17
ITEM 2. Properties	17
ITEM 3. Legal Proceedings	17
ITEM 4. Mine Safety Disclosures	17
PART II	18
ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	18
ITEM 6. [Reserved]	18
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
ITEM 7A. Quantitative and Qualitative Disclosures about Market Risk	22
ITEM 8. Financial Statements and Supplementary Data	22
ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	22
ITEM 9A. Controls and Procedures	22
ITEM 9B. Other Information	24
ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	24
PART III	25
ITEM 10. Directors, Executive Officers and Corporate Governance	25
ITEM 11. Executive Compensation	27
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	29
ITEM 13. Certain Relationships and Related Transactions, and Director Independence	31
ITEM 14. Principal Accounting Fees and Services	31
PART IV	32
ITEM 15. Exhibits and Financial Statement Schedules	32

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents